75 related articles for article (PubMed ID: 17084402)
1. Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome.
Bahia L; Aguiar LG; Villela N; Bottino D; Godoy-Matos AF; Geloneze B; Tambascia M; Bouskela E
Atherosclerosis; 2007 Nov; 195(1):138-46. PubMed ID: 17084402
[TBL] [Abstract][Full Text] [Related]
2. [Effects of rosiglitazone on endothelial function in non-diabetic subjects with metabolic syndrome].
Bahia L; Aguiar LG; Villela N; Bottino D; Godoy-Matos AF; Bouskela E
Arq Bras Cardiol; 2006 May; 86(5):366-73. PubMed ID: 16751941
[TBL] [Abstract][Full Text] [Related]
3. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.
Esposito K; Ciotola M; Carleo D; Schisano B; Saccomanno F; Sasso FC; Cozzolino D; Assaloni R; Merante D; Ceriello A; Giugliano D
Diabetes Care; 2006 May; 29(5):1071-6. PubMed ID: 16644639
[TBL] [Abstract][Full Text] [Related]
4. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance.
de Aguiar LG; Bahia LR; Villela N; Laflor C; Sicuro F; Wiernsperger N; Bottino D; Bouskela E
Diabetes Care; 2006 May; 29(5):1083-9. PubMed ID: 16644641
[TBL] [Abstract][Full Text] [Related]
5. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome.
Wang TD; Chen WJ; Cheng WC; Lin JW; Chen MF; Lee YT
Am J Cardiol; 2006 Oct; 98(8):1057-62. PubMed ID: 17027571
[TBL] [Abstract][Full Text] [Related]
6. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone.
Tack CJ; Ong MK; Lutterman JA; Smits P
Diabetologia; 1998 May; 41(5):569-76. PubMed ID: 9628275
[TBL] [Abstract][Full Text] [Related]
7. [Vascular dysfunction in metabolic disorders: evaluation of some therapeutic interventions].
Bouskela E; Kraemer de Aguiar LG; Nivoit P; Bahia LR; Villela NR; Bottino DA
Bull Acad Natl Med; 2007 Mar; 191(3):475-92; discussion 492-3. PubMed ID: 18072649
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein.
Hung YJ; Lin SH; Pei D; Kuo SW; Hsieh CH; He CT; Hsing Lee C; Fan SC; Sheu WH
Metabolism; 2006 Apr; 55(4):439-44. PubMed ID: 16546473
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction.
Mittermayer F; Schaller G; Pleiner J; Krzyzanowska K; Kapiotis S; Roden M; Wolzt M
J Clin Endocrinol Metab; 2007 Jul; 92(7):2574-80. PubMed ID: 17473072
[TBL] [Abstract][Full Text] [Related]
10. Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome.
Kim SG; Ryu OH; Kim HY; Lee KW; Seo JA; Kim NH; Choi KM; Lee J; Baik SH; Choi DS
Eur J Endocrinol; 2006 Mar; 154(3):433-40. PubMed ID: 16498057
[TBL] [Abstract][Full Text] [Related]
11. Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome.
Bahia L; Aguiar LG; Villela N; Bottino D; Godoy-Matos AF; Geloneze B; Tambascia M; Bouskela E
Clinics (Sao Paulo); 2006 Oct; 61(5):433-40. PubMed ID: 17072441
[TBL] [Abstract][Full Text] [Related]
12. Vitamin C improves endothelial function in healthy estrogen-deficient postmenopausal women.
McSorley PT; Young IS; Bell PM; Fee JP; McCance DR
Climacteric; 2003 Sep; 6(3):238-47. PubMed ID: 14567772
[TBL] [Abstract][Full Text] [Related]
13. Additive Effect of Non-Alcoholic Fatty Liver Disease on Metabolic Syndrome-Related Endothelial Dysfunction in Hypertensive Patients.
Perticone M; Cimellaro A; Maio R; Caroleo B; Sciacqua A; Sesti G; Perticone F
Int J Mol Sci; 2016 Mar; 17(4):456. PubMed ID: 27023537
[TBL] [Abstract][Full Text] [Related]
14. Effects of acquired obesity on endothelial function in monozygotic twins.
Pietiläinen KH; Bergholm R; Rissanen A; Kaprio J; Häkkinen AM; Sattar N; Yki-Järvinen H
Obesity (Silver Spring); 2006 May; 14(5):826-37. PubMed ID: 16855192
[TBL] [Abstract][Full Text] [Related]
15. Troglitazone-induced changes in adiponectin do not affect endothelial function in diabetes.
Buras J; Reenstra WR; Orlow D; Horton ES; Veves A
Obes Res; 2005 Jul; 13(7):1167-74. PubMed ID: 16076985
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome.
Aquilante CL; Kosmiski LA; Zineh I; Rome LC; Knutsen SD
Pharmacotherapy; 2010 Mar; 30(3):236-47. PubMed ID: 20180607
[TBL] [Abstract][Full Text] [Related]
17. Rosiglitazone does not improve vascular function in subjects with chronic kidney disease.
Chan DT; Watts GF; Irish AB; Dogra GK
Nephrol Dial Transplant; 2011 Nov; 26(11):3543-9. PubMed ID: 21378155
[TBL] [Abstract][Full Text] [Related]
18. Pioglitazone improves endothelium-dependent vasodilation in hypertensive patients with impaired glucose tolerance in part through a decrease in oxidative stress.
Hidaka T; Nakagawa K; Goto C; Soga J; Fujii Y; Hata T; Idei N; Fujimura N; Chayama K; Kihara Y; Higashi Y
Atherosclerosis; 2010 Jun; 210(2):521-4. PubMed ID: 20064642
[TBL] [Abstract][Full Text] [Related]
19. Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model.
Sharabi Y; Oron-Herman M; Kamari Y; Avni I; Peleg E; Shabtay Z; Grossman E; Shamiss A
Am J Hypertens; 2007 Feb; 20(2):206-10. PubMed ID: 17261469
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride.
Basu A; Charkoudian N; Schrage W; Rizza RA; Basu R; Joyner MJ
Am J Physiol Endocrinol Metab; 2007 Nov; 293(5):E1289-95. PubMed ID: 17711996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
